However, the administration of CCL5 antagonists or blocking antibodies could prevent both; the progression of atherosclerotic lesions by impairing the chemokine oligomerization45,46 and myocardial injury after infarction, by reducing leukocyte infiltration, chemokine expression and apoptosis in the affected myocardium12,25. The gene discussed is CCL5; the disease is infarction.